These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 2352806)

  • 21. Prostaglandin-induced cortical hyperostosis. Case report and review of the literature.
    Gardiner JS; Zauk AM; Donchey SS; McInerney VK
    J Bone Joint Surg Am; 1995 Jun; 77(6):932-6. PubMed ID: 7782366
    [No Abstract]   [Full Text] [Related]  

  • 22. The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction.
    Chen J; Godschalk M; Katz PG; Mulligan T
    J Urol; 1995 Jan; 153(1):80-1. PubMed ID: 7966797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
    Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prostaglandin E1 in newborn infants with ductus-dependent heart diseases. Review of 40 cases].
    Simões LC; Sarachaga IH; Quero M; Casanova M; Cazzaniga M; Villibre D
    Arq Bras Cardiol; 1985 Jul; 45(1):31-6. PubMed ID: 3938651
    [No Abstract]   [Full Text] [Related]  

  • 25. The harlequin color change and association with prostaglandin E1.
    Rao J; Campbell ME; Krol A
    Pediatr Dermatol; 2004; 21(5):573-6. PubMed ID: 15461766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PGE2 stimulates both resorption and formation of bone in vitro: differential responses of the periosteum and the endosteum in fetal rat long bone cultures.
    Nefussi JR; Baron R
    Anat Rec; 1985 Jan; 211(1):9-16. PubMed ID: 3985383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neonatal transport issues with prostaglandin E1 infusions.
    Grubbs TC; Kraft NL
    Air Med J; 2002; 21(3):8-12. PubMed ID: 11994726
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostaglandin E1 in heart failure: the Vienna experience.
    Pacher R; Stanek B
    Wien Klin Wochenschr; 1996; 108(16):491-5. PubMed ID: 8840496
    [No Abstract]   [Full Text] [Related]  

  • 30. Periosteum: biology, regulation, and response to osteoporosis therapies.
    Allen MR; Hock JM; Burr DB
    Bone; 2004 Nov; 35(5):1003-12. PubMed ID: 15542024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of penile pain after injection of a new formulation of prostaglandin E1.
    Chen J; Godschalk MF; Katz PG; Mulligan T
    J Urol; 1995 Jul; 154(1):77-9. PubMed ID: 7776460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of prostaglandin E1 therapy for sudden deafness.
    Nakashima T; Kuno K; Yanagita N
    Laryngoscope; 1989 May; 99(5):542-6. PubMed ID: 2709943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. To intubate or not to intubate? Transporting infants on prostaglandin E1.
    Meckler GD; Lowe C
    Pediatrics; 2009 Jan; 123(1):e25-30. PubMed ID: 19064611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis.
    Chen RN; Lakin MM; Montague DK; Ausmundson S
    J Urol; 1996 Jan; 155(1):138-40. PubMed ID: 7490812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction.
    Cawello W; Schweer H; Dietrich B; Seyberth HW; Albrecht D; Fox A; Hohmuth H
    J Urol; 1997 Oct; 158(4):1403-7. PubMed ID: 9302131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nursing care of the neonate receiving prostaglandin E1 therapy.
    Rikard DH
    Neonatal Netw; 1993 Jun; 12(4):17-22. PubMed ID: 8510622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.
    Bechara A; Casabé A; Chéliz G; Romano S; Fredotovich N
    J Urol; 1996 Mar; 155(3):913-4. PubMed ID: 8583605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Stasis priapism secondary to PGE1: transformation into high-flow priapism].
    Negrín Díaz A; Díaz Romero F; Fernández Ramos J; Gutiérrez Hernández P; Arteaga Serrano F; Bañares Baudet F
    Actas Urol Esp; 1996 Mar; 20(3):289-91. PubMed ID: 8712048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of the administration of bisphosphonates for the prevention of periosteal bone formation following Moloney sarcoma virus-induced tumors.
    Włodarski P; Włodarski K; Galus K; Luczak M
    Folia Biol (Praha); 1993; 39(6):297-303. PubMed ID: 7926159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uterine rupture with the use of Cervagem (prostaglandin E1) for induction of labour on account of intrauterine death.
    Thavarasah AS; Achanna KS
    Singapore Med J; 1988 Aug; 29(4):351-2. PubMed ID: 3249961
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.